MONOPOTASSIUM GLYCYRRHIZINATE

US Previously Marketed

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C42H59O16.K.2H
Molecular Weight	861.0224
Optical Activity	UNSPECIFIED
Defined Stereocenters	19 / 19
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of MONOPOTASSIUM GLYCYRRHIZINATE

Structure Search

SMILES

[H+].[H+].[K+].[H][C@@]7(O[C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@]2([H])CC[C@@]3(C)[C@@]([H])(CC[C@]4(C)[C@]3([H])C(=O)C=C5[C@]6([H])C[C@](C)(CC[C@]6(C)CC[C@@]45C)C([O-])=O)C2(C)C)C([O-])=O)O[C@@H]([C@@H](O)[C@H](O)[C@H]7O)C([O-])=O

InChI

InChIKey=YLSUMFQEBHBMQB-OOFFSTKBSA-M

InChI=1S/C42H62O16.K/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50;/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54);/q;+1/p-1/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+;/m0./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9570253 | https://www.ncbi.nlm.nih.gov/pubmed/8783808https://www.ncbi.nlm.nih.gov/pubmed/24493924 | https://www.ncbi.nlm.nih.gov/pubmed/19144869 | https://www.ncbi.nlm.nih.gov/pubmed/17613133 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=184.1408http://www.etatpur.co.uk/index.php/enoxolone-sheethttps://www.ncbi.nlm.nih.gov/pubmed/27376261https://www.ncbi.nlm.nih.gov/pubmed/17613133https://www.ncbi.nlm.nih.gov/pubmed/17613133 | http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.3971/pdf | http://www.cosmeticsinfo.org/ingredient/disodium-glycyrrhizate | http://www.google.com.pg/patents/WO2009115455A1https://www.ncbi.nlm.nih.gov/pubmed/17613133 | http://www.cosmeticsinfo.org/ingredient/potassium-glycyrrhetinate
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19429429 | https://www.ncbi.nlm.nih.gov/pubmed/27520483

Potassium Glycyrrhetinate (CAS no. 85985-61-1) is the potassium salt of Glycyrrhetinic Acid. Potassium Glycyrrhetinate is also known as Olean-12-En-29-Oic Acid, 3-Hydroxy-1, 1-Oxo-, Monopotassium Salt. Potassium Glycyrrhetinate functions as a flavoring agent and skin-conditioning agent—miscellaneous in cosmetic products.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
reactive oxygen species metabolic process 68 Target ID: GO:0072593 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19144869	Modulator 828
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha 17 Target ID: Q9UBK2\|\|\|Q3LIG1 Gene ID: 10891.0 Gene Symbol: PPARGC1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24675225	Activator 1430
Alanine aminotransferase 1 17 Target ID: P24298 Gene ID: 2875.0 Gene Symbol: GPT Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10574137	Inhibitor 8297
11-beta-hydroxysteroid dehydrogenase 1 21 Target ID: CHEMBL2391 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19429429	Inhibitor 8297	779.0 nM [IC50]
11-beta-hydroxysteroid dehydrogenase 2 18 Target ID: CHEMBL2908 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19429429	Inhibitor 8297	257.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2578
Inflammation 102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7439375	Primary	Basic research	Unknown Approved Use Unknown
Erythema 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15935505 https://www.ncbi.nlm.nih.gov/pubmed/17252206	Primary	Phase I 428	Unknown Approved Use Unknown
Cardiomyopathy 21 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25298583	Primary	Preclinical	Unknown Approved Use Unknown
Autoimmune hepatitis 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21681505	Primary	Phase I 428	Unknown Approved Use Unknown
Chronic hepatitis C 42 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10574137 https://www.ncbi.nlm.nih.gov/pubmed/9570253 http://www.eisai.com/news/news200744.html	Palliative	Approved 8429	Stronger Neo-Minophagen C Approved Use Chronic Hepatitis C Launch Date 1948
Unknown 2578
Radiodermatitis 16 Sources: https://www.ons.org/intervention/maso65d-xclair%C2%AE	Preventing	Basic research	MASO65D (Xclair®) Approved Use Unknown
Ovarian cancer 157 Sources: http://www.ncbi.nlm.nih.gov/pubmed/25364659	Primary	Basic research	Unknown Approved Use Unknown
Leukemia 87 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27376261	Primary	Basic research	Unknown Approved Use Unknown
Hepatitis B 57 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8783808	Palliative	Not Provided 504	Unknown Approved Use Unknown
Autoimmune hepatitis 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21681505	Palliative	Phase I 428	Unknown Approved Use Unknown
Chronic hepatitis C 42 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9570253	Palliative	Not Provided 504	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
103.89 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18452416	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		ENOXOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1396.97 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18452416	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		ENOXOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
9.46 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18452416	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		ENOXOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
1500 mg single, oral Highest studied dose Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8126129	healthy, 29 years n = 6 Health Status: healthy Age Group: 29 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8126129	Sources: https://pubmed.ncbi.nlm.nih.gov/8126129

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	substrate 1037	substrate 1217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461 MRP1 106 UGT1A3 84	CYP2C19 991 CYP1A2 1054 CYP2E1 667 P-gp 1537 MRP1 107 UGT1A1 418 UGT1A3 422 UGT2B4 249 UGT2B7 389 UGT1A4 347 UGT1A6 307 UGT1A7 236 UGT1A8 283 UGT1A9 380 UGT1A10 291 UGT2B15 203 UGT2B17 213

Drug as perpetrator

Target	Modality	Activity
MRP1 172	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18204840/	likely
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18204840/	likely
UGT1A3 93	inhibitor 3277 Sources: https://static-content.springer.com/esm/art%3A10.1038%2Fsrep09627/MediaObjects/41598_2015_BFsrep09627_MOESM1_ESM.pdf Page: 8.0	yes [IC50 6.12 uM]

Drug as victim

Target	Modality	Activity
MRP1 107	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18204840/ Page: 6.0	likely
CYP3A4 1737	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2042-7158.2012.01516.x Page: 1.0	major
UGT1A3 422	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	major
CYP2C19 991	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2042-7158.2012.01516.x Page: 1.0	minor
CYP2C9 1037	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2042-7158.2012.01516.x Page: 1.0	minor
CYP1A2 1054	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2042-7158.2012.01516.x Page: 1.0	no
CYP2D6 1217	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2042-7158.2012.01516.x Page: 1.0	no
CYP2E1 667	substrate 3367 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.2042-7158.2012.01516.x Page: 1.0	no
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/18204840/ Page: 6.0	no
UGT1A10 291	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	no
UGT1A4 347	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	no
UGT1A6 307	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	no
UGT1A7 236	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	no
UGT1A8 283	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	no
UGT1A9 380	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	no
UGT2B15 203	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	no
UGT2B17 213	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	no
UGT1A1 418	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	yes
UGT2B4 249	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	yes
UGT2B7 389	substrate 3367 Sources: https://www.jstage.jst.go.jp/article/dmpk/24/6/24_6_523/_pdf/-char/en Page: 1.0	yes

Sourcing

Vendor/Aggregator	ID	URL
AEchem Scientific Corp., USA	AE1-006547	http://www.aechemsc.com/info_products/AE1-006547.php
Achemtek	0104-020457	http://www.achemtek.com/471-53-4
Acorn PharmaTech	ACN-036282	http://www.acornpharmatech.com/
Acros Organics	AC120150050	https://www.fishersci.com/shop/products/18-glycyrrhetinic-acid-98-acros-organics/AC120150050
Acros Organics	AC120150250	https://www.fishersci.com/shop/products/18-glycyrrhetinic-acid-98-acros-organics/AC120150250
Aurora Fine Chemicals LLC	A13.139.522	http://online.aurorafinechemicals.com/info?ID=A13.139.522
AvaChem Scientific	1106	http://www.avachem.com/productSearch.asp?1106
Avantor Inc	101179-654	https://us.vwr.com/store/catalog/product.jsp?catalog_number=101179-654
Avantor Inc	200015-658	https://us.vwr.com/store/product/18599070/18-beta-glycyrrhetinic-acid-98
Avantor Inc	700006-634	https://us.vwr.com/store/product/21572407/glycyrrhetic-acid-98
Avantor Inc	700006-636	https://us.vwr.com/store/product/21572407/glycyrrhetic-acid-98
BioSynth	Q-201057	https://www.biosynth.com/en/products/chemical-intermediates/advanced-intermediates/products/Q-201057.html
Boerchem	BC201656	http://www.boerchem.com/?product_33783.html
Chem Scene	CS-W020624	http://www.chemscene.com/471-53-4.html
ChemFaces	CFN99152	http://www.chemfaces.com/natural/Glycyrrhetinic-acid-CFN99152.html
ChemMol	30100980	http://www.chemmol.com/chemmol/30100980.html
ChemMol	30114287	http://www.chemmol.com/chemmol/30114287.html
ChemMol	44000914	http://www.chemmol.com/chemmol/44000914.html
ChemMol	99088065	http://www.chemmol.com/chemmol/99088065.html
Chemspace	CSSB00020617985	https://chem-space.com/CSSB00020617985
China MainChem Co., Ltd	471-53-4	https://www.mainchem.com/product/china-enoxolone-cas-471-53-4-glycyrrhetinic-acid-supplier/
DC Chemicals	DCG-032	http://www.dcchemicals.com//product_show-18_beta_Glycyrrhetintic_Acid.html
Glentham Life Sciences	GP8041	http://www.glentham.com/products/product/GP8041/
Hairui	HR135798	http://www.hairuichem.com/en/product/471-53-4.html
Herbest Bio-Tech	HH231694	http://www.bjherbest.com/analytical-standard/saponins/18-beta-glycyrrhetinic-acid-471-53-4.html
LGC Standards	DRE-A13167700AL-100	https://www.lgcstandards.com/US/en/p/DRE-A13167700AL-100
LGC Standards	DRE-C13167700	https://www.lgcstandards.com/US/en/p/DRE-C13167700
LGC Standards	MM3399.00	https://www.lgcstandards.com/US/en/p/MM3399.00
Lab Network	LN00839314	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00839314
MedChem Express	HY-N0180	https://www.medchemexpress.com/18_beta_-Glycyrrhetinic_acid.html
MuseChem	R048750	https://www.musechem.com/product/R048750.html
OChem	3435	http://www.ocheminc.com/index.php?act=psearch&pid=471G534
Oakwood	103973	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=194966&ExtHyperLink=1
R&D Chemicals	43	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=7860
Sigma-Aldrich	G10105_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/g10105?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	50510_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/50510?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	E0180500_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/e0180500?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S527188	http://www.smolecule.com/products/s527188
TCI (Tokyo Chemical Industry)	G0149	http://www.tcichemicals.com/eshop/en/us/commodity/G0149/index.html
THE BioTek	bt-267335	https://www.thebiotek.com/product/inhibitors/bt-267335
VladaChem	VL277837-1G	https://www.vladachem.com/product.php?products=471-53-4
Yuhao Chemical	JZ1453	http://www.chemyuhao.com/471-53-4.html
abcr GmbH	AB136427	http://www.abcr.com/shop/en/AB136427
eNovation Chemicals	D676398	https://www.enovationchem.com/ProductDetails.asp?ProductID=D676398
eNovation Chemicals	D765568	https://www.enovationchem.com/ProductDetails.asp?ProductID=D765568
mcule	MCULE-4676598997	https://mcule.com/MCULE-4676598997/

PubMed

Title	Date	PubMed
Therapeutic basis of glycyrrhizin on chronic hepatitis B.	1996 May	8783808
Review article: glycyrrhizin as a potential treatment for chronic hepatitis C.	1998 Mar	9570253
[The assessment of safety of enoxaparin administration during percutaneous transluminal coronary angioplasty after ticlopidine pretreatment. Application of low molecular weigh heparins in prevention of coronary micro-embolization].	2001	11816736
The enhancement of glucose uptake caused by the collapse of gap junction communication is due to an increase in astrocyte proliferation.	2001 Aug	11520909
18-beta-Glycyrrhetinic acid (BGA) as an electrical uncoupler for intracellular recordings in confluent monolayer cultures.	2001 Aug	11512024
Inhibitory effect of glycyrrhizin on the phosphorylation and DNA-binding abilities of high mobility group proteins 1 and 2 in vitro.	2001 Aug	11510483
Antibacterial compounds of licorice against upper airway respiratory tract pathogens.	2001 Jun	11575586
Potentiation of L-type calcium channels reveals nonsynaptic mechanisms that correlate spontaneous activity in the developing mammalian retina.	2001 Nov 1	11606640
[Prevention of development of hepatocellular carcinoma from HCV-associated liver cirrhosis by multi-agents therapy including stronger-neo-minophagen C].	2001 Oct	11762054
Simultaneous determination of glycyrrhizin, glycyrrhetic acid and glycyrrhetic acid mono-glucuronide in Shakuyaku-kanzo-to incubated with rat feces by semi-micro high-performance liquid chromatography.	2001 Oct	11642324
Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.	2001 Oct	11606334
Bimodal inhibition of connexin 43 gap junctions decreases ACTH-induced steroidogenesis and increases bovine adrenal cell population growth.	2001 Oct	11572804
Modulation of 11 beta-hydroxysteroid dehydrogenase type 2 activity in Ishikawa cells is associated with changes in cellular proliferation.	2001 Oct 25	11604236
Therapeutic effect of glycyrrhetinic acid in MRL lpr/lpr mice: implications of alteration of corticosteroid metabolism.	2001 Oct 5	11681629
[Licorice-induced pseudoaldosteronism in a patient with a non-functioning adrenal tumor].	2001 Sep	11692600
Characterization of secretory type IIA phospholipase A2 (sPLA2-IIA) as a glycyrrhizin (GL)-binding protein and the GL-induced inhibition of the CK-II-mediated stimulation of sPLA2-IIA activity in vitro.	2001 Sep	11558558
An unexpected case of primary pulmonary hypertension of the neonate (PPHN). Potential role of topical administration of enoxolone.	2002	12442611
Molecular pharmacophore determination of lipid lowering drugs with the receptor mapping method.	2002 Apr	12370071
Glycyrrhizic acid suppresses type 2 11 beta-hydroxysteroid dehydrogenase expression in vivo.	2002 Apr	11983491
Retinoids inhibit squamous cell carcinoma growth and intercellular communication.	2002 Apr	11922733
Kinetics and mechanism of intercellular ice propagation in a micropatterned tissue construct.	2002 Apr	11916845
Coordination of mesangial cell contraction by gap junction--mediated intercellular Ca(2+) wave.	2002 Aug	12138132
Cell coupling and Cx43 expression in embryonic mouse neural progenitor cells.	2002 Aug 15	12140256
Short-term cortisol infusion in the brachial artery, with and without inhibiting 11 beta-hydroxysteroid dehydrogenase, does not alter forearm vascular resistance in normotensive and hypertensive subjects.	2002 Dec	12534445
Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity.	2002 Dec	12466364
Inhibitors of gap junctions attenuate myogenic tone in cerebral arteries.	2002 Dec	12427590
Smooth muscle membrane potential modulates endothelium-dependent relaxation of rat basilar artery via myo-endothelial gap junctions.	2002 Dec 15	12482900
[Effects of glycyrrhetinic acid and IFN-alpha on HSCs collagen metabolism in rat fibrotic liver of varying stages].	2002 Feb	11856516
11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase.	2002 Feb 19	11841241
Induction of inducible nitric oxide synthase expression by 18beta-glycyrrhetinic acid in macrophages.	2002 Feb 27	11904152
Primary afferent fibers establish dye-coupled connections in the frog central nervous system.	2002 Feb-Mar 1	11922980
[Quantitative determinations of glycyrrhizic acid, glycyrrhetinic acid, morphine and sodium benzoate in compound liquorice tablets by capillary zone electrophoresis].	2002 Jan	12541626
Influence of honey on the gastrointestinal metabolism and disposition of glycyrrhizin and glycyrrhetic acid in rabbits.	2002 Jan	11824564
Stimulation of the BK(Ca) channel in cultured smooth muscle cells of human trachea by magnolol.	2002 Jan	11809993
Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria.	2002 Jan	11752037
Critical role of gap junctions in endothelium-dependent hyperpolarization in rat mesenteric arteries.	2002 Jul	12060103
IL-1beta-induced production of metalloproteinases by synovial cells depends on gap junction conductance.	2002 Jun	11997239
Metabolism of constituents in Huangqin-Tang, a prescription in traditional Chinese medicine, by human intestinal flora.	2002 May	12033492
Foetal lung maturation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice.	2002 Oct	12439781
11beta-hydroxysteroid dehydrogenase type 1: a new regulator of fetal lung maturation.	2002 Oct	12439780
Modulation of renal calcium handling by 11 beta-hydroxysteroid dehydrogenase type 2.	2002 Oct	12239243
Inhibition of 3 alpha/beta,20 beta-hydroxysteroid dehydrogenase by dexamethasone, glycyrrhetinic acid and spironolactone is attenuated by deletion of 12 carboxyl-terminal residues.	2002 Sep	12230123
Subjects with essential hypertension are more sensitive to the inhibition of 11 beta-HSD by liquorice.	2003 Feb	12574791
Biological activities of synthetic saponins and cardiac glycosides.	2003 Jan	12557254
Photoliberating inositol-1,4,5-trisphosphate triggers ATP release that is blocked by the connexin mimetic peptide gap 26.	2003 Jan	12526886
Blockade of brain stem gap junctions increases phrenic burst frequency and reduces phrenic burst synchronization in adult rat.	2003 Jan	12522166
Final report on the safety assessment of Glycyrrhetinic Acid, Potassium Glycyrrhetinate, Disodium Succinoyl Glycyrrhetinate, Glyceryl Glycyrrhetinate, Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and Potassium Glycyrrhizinate.	2007	17613133
Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds.	2008 Jun	18446848
Ammonium glycyrrhizinate protects gastric epithelial cells from hydrogen peroxide-induced cell death.	2009 Mar	19144869
Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models.	2014	24493924

Patents

Sample Use Guides

In Vivo Use Guide

100 ml/day of intravenous glycyrrhizin

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Name

Type

Language

MONOPOTASSIUM GLYCYRRHIZINATE

Common Name

English

MONOPOTASSIUM GLYCYRRHIZATE

Common Name

English

.ALPHA.-D-GLUCOPYRANOSIDURONIC ACID, (3.BETA.,20.BETA.)-20-CARBOXY-11-OXO-30-NOROLEAN-12-EN-3-YL 2-O-.BETA.-D-GLUCOPYRANURONOSYL-, POTASSIUM SALT (1:1), (3.BETA.)-

Systematic Name

English

18.BETA.-GLYCYRRHIZIC ACID MONOPOTASSIUM SALT

Common Name

English

Glycyrrhizinate potassium [WHO-DD]

Common Name

English

.ALPHA.-D-GLUCOPYRANOSIDURONIC ACID, (3.BETA.,20.BETA.)-20-CARBOXY-11-OXO-30-NOROLEAN-12-EN-3-YL 2-O-.BETA.-D-GLUCOPYRANURONOSYL-, MONOPOTASSIUM SALT

Common Name

English

Code System Code Type Description

CAS

42294-03-1